Powder: -20°C for 3 years | In solvent: -80°C for 1 year
AKOS037652256 can be used as a TRPML modulator for the treatment of diseases associated with TRPML activity such as lysosomal accumulation disorders, muscular dystrophy, common age-related neurodegenerative diseases, oxidative stress or reactive oxygen species (ROS)-related diseases and ageing.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 195.00 | |
5 mg | In stock | $ 440.00 | |
10 mg | In stock | $ 648.00 | |
25 mg | In stock | $ 987.00 | |
50 mg | In stock | $ 1,390.00 | |
100 mg | In stock | $ 1,870.00 |
Description | AKOS037652256 can be used as a TRPML modulator for the treatment of diseases associated with TRPML activity such as lysosomal accumulation disorders, muscular dystrophy, common age-related neurodegenerative diseases, oxidative stress or reactive oxygen species (ROS)-related diseases and ageing. |
Targets&IC50 | TRPML:< = 2 µM(AC50), TRPML1:< = 2 µM(AC50) |
In vitro | AKOS037652256 (Compound 8) (0.1-3 μM) was sufficient to induce TFEB-nuclear translocation (nuclear to cytosol ratio increased in a dose-dependent manner.[2] |
Molecular Weight | 553.07 |
Formula | C24H26ClFN4O4S2 |
CAS No. | 2171065-77-1 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 5.53 mg/mL (10 mM), Sonication is recommended.
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
AKOS037652256 2171065-77-1 inhibitor inhibit